| Schedule of Company’s Segment |
The
following table presents the Company’s segment results (unaudited) for the six months and three months ended June 30, 2026 and
2025:
Schedule
of Company’s Segment
| | |
Medical Device | | |
Digital Asset Treasury | | |
Corporate | | |
Consolidated | | |
Medical
Device DO | | |
Digital Asset Treasury | | |
Corporate | | |
Consolidated | |
| | |
SIX
MONTHS
ENDED
JUNE 30, 2026
| | |
SIX
MONTHS
ENDED
JUNE 30, 2025
| |
| | |
Medical Device | | |
Digital Asset Treasury | | |
Corporate | | |
Consolidated | | |
Medical
Device DO | | |
Digital Asset Treasury | | |
Corporate | | |
Consolidated | |
| Net Revenue | |
$ | 192,780 | | |
$ | - | | |
$ | - | | |
$ | 192,780 | | |
$ | 136,080 | | |
$ | - | | |
$ | - | | |
$ | 136,080 | |
| Cost of goods sold | |
| 202,578 | | |
| - | | |
| - | | |
| 202,578 | | |
| 148,620 | | |
| - | | |
| - | | |
| 148,620 | |
| Cost of goods sold - inventory reserve | |
| 284,228 | | |
| - | | |
| - | | |
| 284,228 | | |
| - | | |
| - | | |
| - | | |
| - | |
| Total Cost of Goods Sold | |
| 486,806 | | |
| - | | |
| - | | |
| 486,806 | | |
| 148,620 | | |
| - | | |
| - | | |
| 148,620 | |
| Gross Margin (Loss) | |
| (294,026 | ) | |
| - | | |
| - | | |
| (294,026 | ) | |
| (12,540 | ) | |
| - | | |
| - | | |
| (12,540 | ) |
| | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Staking Revenue, net | |
| - | | |
| 5,457,656 | | |
| - | | |
| 5,457,656 | | |
| - | | |
| - | | |
| - | | |
| - | |
| | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Operating expenses: | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Consulting fees – related parties | |
| - | | |
| 5,000,000 | | |
| - | | |
| 5,000,000 | | |
| - | | |
| - | | |
| - | | |
| - | |
| Selling, general and administrative | |
| 158,720 | | |
| 55,000 | | |
| 10,002,860 | | |
| 10,216,580 | | |
| 497,050 | | |
| - | | |
| 2,278,407 | | |
| 2,775,457 | |
| Research and development | |
| - | | |
| - | | |
| 420,255 | | |
| 420,255 | | |
| - | | |
| - | | |
| - | | |
| - | |
| Unrealized loss on digital commodities | |
| - | | |
| 84,336,553 | | |
| - | | |
| 84,336,553 | | |
| - | | |
| - | | |
| - | | |
| - | |
| Realized loss on digital commodities | |
| - | | |
| 14,716,799 | | |
| - | | |
| 14,716,799 | | |
| - | | |
| - | | |
| - | | |
| - | |
| Digital commodity transaction expenses | |
| - | | |
| 128,508 | | |
| - | | |
| 128,508 | | |
| - | | |
| - | | |
| - | | |
| - | |
| Total Operating Expenses | |
| 158,720 | | |
| 104,236,860 | | |
| 10,423,115 | | |
| 114,818,695 | | |
| 497,050 | | |
| - | | |
| 2,278,407 | | |
| 2,775,457 | |
| Loss from Operations | |
| (452,746 | ) | |
| (98,779,204 | ) | |
| (10,423,115 | ) | |
| (109,655,065 | ) | |
| (509,590 | ) | |
| - | | |
| (2,278,407 | ) | |
| (2,787,997 | ) |
| | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Other Income: | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Interest expense, net | |
| - | | |
| 57,517 | | |
| 29,267 | | |
| 86,784 | | |
| - | | |
| - | | |
| (530,038 | ) | |
| (530,038 | ) |
| Fair market value adjustment on warrants | |
| - | | |
| - | | |
| 47,919 | | |
| 47,919 | | |
| - | | |
| - | | |
| 11,087,700 | | |
| 11,087,700 | |
| Other expense | |
| - | | |
| - | | |
| 329 | | |
| 329 | | |
| - | | |
| - | | |
| (12 | ) | |
| (12 | ) |
| Total Other Income | |
| - | | |
| 57,517 | | |
| 77,515 | | |
| 135,032 | | |
| - | | |
| - | | |
| 10,557,649 | | |
| 10,557,649 | |
| Tax Provision | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | |
| Income (Loss) from Continuing Operations | |
$ | (452,746 | ) | |
$ | (98,721,687 | ) | |
$ | (10,345,600 | ) | |
$ | (109,520,033 | ) | |
$ | (509,590 | ) | |
$ | - | | |
$ | 8,279,242 | | |
$ | 7,769,651 | |
| | |
Medical Device | | |
Digital Asset Treasury | | |
Corporate | | |
Consolidated | | |
Medical
Device DO | | |
Digital Asset Treasury | | |
Corporate | | |
Consolidated | |
| | |
THREE
MONTHS
ENDED
JUNE 30, 2026
| | |
THREE
MONTHS
ENDED
JUNE 30, 2025
| |
| | |
Medical Device | | |
Digital Asset Treasury | | |
Corporate | | |
Consolidated | | |
Medical
Device DO | | |
Digital Asset Treasury | | |
Corporate | | |
Consolidated | |
| Net Revenue | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | 136,080 | | |
$ | - | | |
$ | - | | |
$ | 136,080 | |
| Cost of goods sold | |
| - | | |
| - | | |
| - | | |
| - | | |
| 148,620 | | |
| - | | |
| - | | |
| 148,620 | |
| Cost of goods sold - inventory reserve | |
| 284,228 | | |
| - | | |
| - | | |
| 284,228 | | |
| - | | |
| - | | |
| - | | |
| - | |
| Total Cost of Goods Sold | |
| 284,228 | | |
| - | | |
| - | | |
| 284,228 | | |
| 148,620 | | |
| - | | |
| - | | |
| 148,620 | |
| Gross Margin (Loss) | |
| (284,228 | ) | |
| - | | |
| - | | |
| (284,228 | ) | |
| (12,540 | ) | |
| - | | |
| - | | |
| (12,540 | ) |
| | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Staking Revenue, net | |
| - | | |
| 2,323,547 | | |
| - | | |
| 2,323,547 | | |
| - | | |
| - | | |
| - | | |
| - | |
| | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Operating expenses: | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Consulting fees – related parties | |
| - | | |
| 2,500,000 | | |
| - | | |
| 2,500,000 | | |
| - | | |
| - | | |
| - | | |
| - | |
| Selling, general and administrative | |
| 80,729 | | |
| 40,000 | | |
| 5,042,528 | | |
| 5,163,257 | | |
| 69,968 | | |
| - | | |
| 1,341,193 | | |
| 1,411,161 | |
| Research and development | |
| - | | |
| - | | |
| 283,158 | | |
| 283,158 | | |
| - | | |
| - | | |
| - | | |
| - | |
| Unrealized loss on digital commodities | |
| - | | |
| 13,490,351 | | |
| - | | |
| 13,490,351 | | |
| - | | |
| - | | |
| - | | |
| - | |
| Realized loss on digital commodities | |
| - | | |
| 3,926,958 | | |
| - | | |
| 3,926,958 | | |
| - | | |
| - | | |
| - | | |
| - | |
| Digital commodity transaction expenses | |
| - | | |
| 64,686 | | |
| - | | |
| 64,686 | | |
| | | |
| - | | |
| - | | |
| - | |
| Total Operating Expenses | |
| 80,729 | | |
| 20,021,995 | | |
| 5,325,686 | | |
| 25,428,410 | | |
| 69,968 | | |
| - | | |
| 1,341,193 | | |
| 1,411,161 | |
| Loss from Operations | |
| (364,957 | ) | |
| (17,698,448 | ) | |
| (5,325,686 | ) | |
| (23,389,091 | ) | |
| (82,508 | ) | |
| - | | |
| (1,341,193 | ) | |
| (1,423,701 | ) |
| | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Other Income: | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Interest expense, net | |
| - | | |
| 76,746 | | |
| - | | |
| 76,746 | | |
| - | | |
| - | | |
| 96,953 | | |
| 96,953 | |
| Fair market value adjustment on warrants | |
| - | | |
| - | | |
| 31,211 | | |
| 31,211 | | |
| - | | |
| - | | |
| 6,468,811 | | |
| 6,468,811 | |
| Other expense | |
| - | | |
| - | | |
| 336 | | |
| 336 | | |
| - | | |
| - | | |
| (12 | ) | |
| (12 | ) |
| Total Other Income | |
| - | | |
| 76,746 | | |
| 31,547 | | |
| 108,293 | | |
| - | | |
| - | | |
| 6,565,751 | | |
| 6,565,751 | |
| Tax Provision | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | |
| Income (Loss) from Continuing Operations | |
$ | (364,957 | ) | |
$ | (17,621,702 | ) | |
$ | (5,294,139 | ) | |
$ | (23,280,798 | ) | |
$ | (82,508 | ) | |
$ | - | | |
$ | 5,224,558 | | |
$ | 5,142,049 | |
The
following table presents the total assets by segment (unaudited) at June 30, 2026 and December 31, 2025:
| June 30, 2026 | | |
DECEMBER 31, 2025 | |
Medical
Device | | |
Digital
Commodities | | |
Corporate | | |
Consolidated | | |
Medical
Device | | |
Digital
Commodities | | |
Corporate | | |
Consolidated | |
| $ | 570,381 | | |
$ | 146,188,981 | | |
$ | 13,591,213 | | |
$ | 160,350,575 | | |
$ | 849,388 | | |
$ | 257,253,661 | | |
$ | 10,972,124 | | |
$ | 269,075,172 | |
Note:
Net Loss by Segment includes Corporate, although not a reportable segment, only for reconciliation to the condensed consolidated statement
of operations.
|